A Prospective, Open Label, Non Randomized, Clinical Study to Evaluate the Safety and Effectiveness of the Eraser Tattoo Removal Device
NCT00904631 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2009-05-20
Summary
Name of Device: Eraser Tattoo Removal Device
Device Description: The Eraser device is a mechanical device, resembling tattoo devices but with an innovative mechanism for dripping treatment fluid over reciprocating needles and returning used fluid into a reservoir chamber. The device is intended for removal of tattoos.
Objectives: This study is a continuation of a previous feasibility study, which tested the ability of the device to remove tattoos from small skin areas. The purpose of this study is to evaluate the safety and effectiveness of the Eraser Tattoo Removal system for removal of skin tattoos in their entirety.
Subject Population: 20 patients in the medical center. Subject enrollment will include (i) a variety of tattoo colors (multiple colors) (ii) a variety of tattoo composition, contour lines and shadings (iii) Subjects with different skin colors (white, tanned, dark, etc…) (iv) professional and amateur tattoos.
Structure: A prospective, non-randomized, open, clinical study designed according to FDA guidelines; ISO 14155: standard for clinical studies of medical devices; and the procedures of the Israeli Ministry of Health for clinical studies.
After informed consent is signed, demographic details and medical history will be taken and a physical examination performed. Subjects will be treated with the Eraser device, using salicylic acid (5%) as washing fluid. The skin will be examined by a physician and the tattoo area will be photographed. The Eraser device will be used to remove the tattoo from the entire tattoo area (up to 30 minutes in a single session). An absorbent bandage will be put on the treated area for one-hour post treatment. After Care Treatment, based on a Dermatologist's consultation, will be performed on a case-by-case basis (for example, use of antibiotic ointments in case of infection). All subjects must refrain from exposure to the sun for 90 days following each treatment.
Follow-up: The subject will return for follow-up at one week, two weeks, 1 month and two months (if tattoo removal and skin healing is complete), or up to six months (if skin healing/ tattoo removal are not complete by two months), or until the healing of the tattoo removal site is completely resolved or until the investigator determines that additional treatments will provide no further benefit to the patient. In each follow-up visit, a physician will perform a physical examination, check the skin over and around the treatment area, and take photographs of the treated area. Images from last follow-up will be compared with images of the same site taken before the removal procedure, for evaluation of treatment efficacy and safety.
Repeat treatments: if tattoo removal is not complete, up to two additional treatments will be performed, based on the investigator's discretion. After each treatment, follow-up will continue as described above.
Blinding: Non-Applicable Concurrent Control: There is no concurrent control group in this study. Images of tattoos before treatment will serve as the reference measure, to which images of healed skin, several weeks after tattoo removal, will be compared.
Sample Size: 20 subjects will be enrolled in the study. Primary Effectiveness Variables: The primary measure of effectiveness will be the pigment clearance, as evaluated by image comparison on a 1-5 analog scale (5 - 81-100% clearance- excellent removal; 4 - 61-80% - good removal; 3 - 41-60% - moderate removal; 2 - 21-40% - fair removal; 1 - 0-20% - poor removal). Effectiveness will be calculated for the total study group and for individual sub-groups (skin type, pigment colors, etc.). Effectiveness will be analyzed separately for the area affected (percentage of treated area that showed any reaction to treatment) and for the change in color brightness (if, due to technical reasons, part of the tattoo showed a major effect, this area will be evaluated for the change in color brightness). For both analyses, the same scale will be used.
For safety assessment, the rate of systemic and dermatologic adverse events will be calculated and reported. The data will be listed by type of event and by severity. Specifically, textural change, hypo- and hyper- pigmentation will be followed and their rates calculated.
Data Analysis: For this clinical study, descriptive statistics will be used. Successful treatment will be a result of 3 or more (at least, moderate tattoo removal) on the brightness change scale.
Study Sponsor: Hawk Medical Technologies Ltd.
Conditions
- Removal of Colors Tattoo (Multiple Colors)
Interventions
- DEVICE
-
Eraser device+ salicylic acid (5%)
Subjects will be treated with the Eraser device, using salicylic acid (5%) as washing fluid. The skin will be examined by a physician and the tattoo area will be photographed. The Eraser device will be used to remove the tattoo from the entire tattoo area (up to 30 minutes in a single session). An absorbent bandage will be put on the treated area for one-hour post treatment. After Care Treatment, based on a Dermatologist's consultation, will be performed on a case-by-case basis (for example, use of antibiotic ointments in case of infection).
Sponsors & Collaborators
-
Assaf-Harofeh Medical Center
lead OTHER_GOV
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2009-05-31
- Primary Completion
- 2010-05-31
- Completion
- 2010-08-31
Countries
- Israel
Study Locations
More Related Trials
-
Laser Treatment of Tattoos With Pico Laser
NCT02146807 ·Status: COMPLETED ·Phase: NA
-
Evaluation of the 755nm Alexandrite Laser for the Treatment of Tattoos
NCT01754207 ·Status: COMPLETED ·Phase: NA
-
Multi-Wavelength Laser Tattoo Removal Pivotal Study
NCT02935660 ·Status: COMPLETED ·Phase: NA
-
The Efficacy of the Cupola Ultrasonic Tattoo Removal Device
NCT01516034 ·Status: TERMINATED ·Phase: NA
-
Picosure Alexandrite Laser for the Treatment of Unwanted Tattoos
NCT02110095 ·Status: COMPLETED ·Phase: NA
-
Clinical Study to Evaluate the Performance of the PicoWayTM 1064 nm/ 785 nm/ 532nm Picosecond Laser for Tattoo Removal
NCT02700932 ·Status: UNKNOWN ·Phase: NA
-
Soliton Planar Acoustic Wave Device System for Dermal Tattoo Clearing Human Trial Protocol
NCT03125824 ·Status: COMPLETED ·Phase: NA
-
Evaluating the Safety and Performance Characteristics of Ephemeral® Tattoo Ink in Healthy Subjects
NCT05877833 ·Status: COMPLETED
-
Soliton Planar Acoustic Wave Device System for Dermal Clearing Human Trial Protocol
NCT02877667 ·Status: COMPLETED ·Phase: NA
-
Safety for Frequent Use Conditions of Hair Removal Device
NCT01348789 ·Status: COMPLETED ·Phase: NA
-
An Open-label, Non Significant Risk, Adhesive Wear Validation Study for the On Body Drug Delivery Device Component of the SQIN-01 Furosemide Infusor (Infusor Device)
NCT04836572 ·Status: COMPLETED ·Phase: NA
-
Assess Safety and Performance of the Kronos Electrocautery Device for Electrocautery Procedures Following Coaxial Biopsy Procedures
NCT05593211 ·Status: COMPLETED ·Phase: NA
-
Investigation to Evaluate Performance and Safety of RemovAid ™ in Removal of Contraceptive Implants
NCT03912649 ·Status: TERMINATED ·Phase: NA
-
A Randomized Controlled Trial of No Strings Intrauterine Device (IUD) Removal Techniques
NCT05702242 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Lutronic PicoPlus Exploratory Clinical Trial
NCT03415685 ·Status: TERMINATED ·Phase: NA
-
Treatment of SARS-CoV-2 Virus Disease (COVID-19) in Humans With Hemopurifier® Device
NCT04595903 ·Status: TERMINATED ·Phase: NA
-
The Lumen Study: Comparing Devices for Patients With Symptomatic Femoro-popliteal Chronic Total Occlusion (CTO)
NCT02145299 ·Status: TERMINATED ·Phase: PHASE2
-
Novel Guidance Device for Image Fusion and Needle Guidance in Lung, Liver or Kidney Biopsy
NCT04039529 ·Status: WITHDRAWN ·Phase: NA
-
CONNECT: A Multi-Cohort, Prospective Investigation of the Symani® Surgical System
NCT06866197 ·Status: RECRUITING ·Phase: NA
-
Safety Study of the Aethlon Hemopurifier
NCT02215902 ·Status: TERMINATED ·Phase: NA
-
Preliminary Evaluation of a "Clip" Device for Contraceptive Implant Removal
NCT04919395 ·Status: TERMINATED ·Phase: NA
-
Clinical Evaluation of the CM-1500 During Apheresis Blood Donation
NCT05012462 ·Status: COMPLETED ·Phase: NA
-
Minimally-Invasive Realtime Assessment of Continuous Lactate in Exercise
NCT04238611 ·Status: UNKNOWN ·Phase: NA
-
A Single Arm, Open-label First In Human Study for Assessing the Safety and Performance of the EpiFinder in Subjects With Clinical Indication for Lumbar Epidural Steroids Injection (ESI)
NCT04047927 ·Status: UNKNOWN ·Phase: NA
-
Pilot Study of Suction as a Mechanism of IUD Expulsion With Concomitant Menstrual Cup Use
NCT05254041 ·Status: RECRUITING ·Phase: NA